CINCINNATI, OHIO, September 16, 2025 – Meridian Bioscience, Inc., a global leader in diagnostics and life science raw materials, has introduced the industry’s first liquid qPCR master mixes proven stable for more than 12 months at ambient temperatures, a development that removes the need for refrigeration, freezing, or costly lyophilization. The breakthrough promises to cut supply chain costs, simplify logistics, and provide unprecedented flexibility for assay developers in molecular diagnostics.
Science Significance
This launch marks a scientific milestone in molecular biology and diagnostics. Traditional qPCR reagents depend on cold chain or lyophilized formulations to maintain stability, but Meridian’s new liquid mixes—stable at room temperature and even at 50°C—open new possibilities for point-of-care testing, decentralized labs, and global distribution. By proving that liquid formulations can retain full performance for more than 12 months, Meridian has expanded the technical frontier for nucleic acid amplification reagents, providing researchers and developers with tools that increase scalability without sacrificing accuracy.
Regulatory Significance
From a regulatory perspective, the new master mixes will influence assay validation and compliance. Reagents that eliminate cold chain reduce variability and risk during transport, helping laboratories meet quality standards more consistently. Furthermore, the stability of these products over extended timeframes may allow regulatory agencies to consider simplified labeling, broader shipping allowances, and reduced biosafety risks during distribution. In global markets where regulatory frameworks increasingly emphasize sustainability and cost-effectiveness, Meridian’s innovation could serve as a model for future regulatory guidance on ambient-stable biologics.
Business Significance
Advertisement
The business impact of this launch is substantial. Maintaining cold chain logistics contributes heavily to diagnostics supply costs—spanning refrigerated storage, specialized transport, and risk of spoilage. By removing cold chain requirements, Meridian enables assay developers to scale manufacturing and distribution more cost-effectively. The company’s two formats—Liquid Stable Ready Mix (MDX364) for ready-to-use assays, and Liquid Stable Flex Mix (MDX360) for customizable applications—position Meridian as a leader in the $10+ billion molecular reagents market. These formats are particularly valuable to manufacturers supplying high-throughput platforms, contract research organizations, and decentralized diagnostic networks worldwide.
Patients’ Significance
At the patient level, the implications are equally profound. Diagnostics that no longer rely on refrigeration can reach underserved regions, including rural hospitals, resource-limited clinics, and global health programs. Faster, more scalable testing empowers providers to detect diseases with greater accuracy and efficiency. Patients in point-of-care settings will benefit from shorter turnaround times, reduced costs, and improved reliability, ultimately supporting earlier interventions and better health outcomes. The elimination of cold chain dependency also ensures continuity of care in emergency response situations, where refrigeration is often unavailable.
Policy Significance
On the policy front, Meridian’s breakthrough aligns with global healthcare priorities. Governments and health organizations are pushing for sustainable, cost-effective diagnostic solutions, especially in light of climate concerns and the environmental impact of refrigeration. Ambient-stable technologies directly support these goals by reducing energy consumption and carbon footprint across healthcare supply chains. The advancement may prompt policymakers to incentivize wider adoption of ambient-stable reagents in public health systems, thereby fostering greater resilience in pandemic preparedness and routine care delivery.
Transaction Highlights
Meridian Bioscience has launched the industry’s first liquid qPCR master mixes proven stable for more than 12 months at ambient temperature, eliminating the need for refrigeration, freezing, or lyophilization. The company introduced two distinct product formats: the Liquid Stable Ready Mix (MDX364), formulated for manufacturers creating ready-to-use assays with demonstrated stability at room temperature and even after two weeks at 50°C in the presence of oligos; and the Liquid Stable Flex Mix (MDX360), designed for maximum flexibility, enabling end-users to add primers and probes at the point of use while maintaining full functionality for over 12 months without cold chain. Together, these innovations reduce costs, simplify logistics, support automation, and expand access to reliable molecular diagnostics across centralized labs, high-throughput environments, and point-of-care settings worldwide.
Source: Meridian Bioscience, Inc. Press Release
